United States · Platforms & data · The Motley Fool

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Published by The Motley Fool · United States 2 h ago

Revenue fell 52% on delivery timing, but debt dropped 55% and guidance rose on margins.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Abbott Laboratories (NYSE:ABT) Stock Sale Revealed by Rep. Thomas H. Kean, Jr.

Michael Burry adds to BYD, SFM, JD, sees up to 140% potential in Fiserv

Blackstone president calls for more equity to fund AI buildout as debt risks mount

Why is Virgin Australia stock surging today?

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Apple Tops Estimates but Shares Fall After Hours on Poor Margin Guidance